title: The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
authors: University of Sydney, Sydney, New South Wales, Australia.
authors: Danuta S
authors: DS
authors: Kalinowski
authors: Patric J
authors: PJ
authors: Jansson
authors: Zaklina
authors: Z
authors: Kovacevic
authors: Des R
authors: DR
authors: Richardson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003300:Copper / Q000378:metabolism*; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D013882:Thiosemicarbazones / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D007502:Iron Chelating Agents; D013882:Thiosemicarbazones; D003300:Copper